Format

Send to

Choose Destination
See comment in PubMed Commons below
Molecules. 2015 Apr 8;20(4):6068-92. doi: 10.3390/molecules20046068.

Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.

Author information

1
Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Yufu 879-5593, Japan. miphto@oita-u.ac.jp.
2
Gastroentero-Hepatology Division, Department of Internal Medicine, Airlangga University Faculty of Medicine, Surabaya 60131, Indonesia. miphto@oita-u.ac.jp.
3
Institute of Tropical Disease, Airlangga University, Surabaya 60115, Indonesia. miphto@oita-u.ac.jp.
4
Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Yufu 879-5593, Japan. yyamaoka@oita-u.ac.jp.
5
Department of Gastroenterology and Hepatology, Baylor College of Medicine and Michael DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA. yyamaoka@oita-u.ac.jp.

Abstract

Asia has the largest population of any continent and the highest incidence of gastric cancer in the world, making it very important in the context of Helicobacter pylori infection. According to current guidelines, standard triple therapy containing a proton pump inhibitor (PPI) and two antibiotics; amoxicillin (AMX) and clarithromycin (CAM) or metronidazole (MNZ), is still the preferred first-line regimen for treatment of H. pylori infection. However, the efficacy of legacy triple regimens has been seriously challenged, and they are gradually becoming ineffective. Moreover, some regions in Asia show patterns of emerging antimicrobial resistance. More effective regimens including the bismuth and non-bismuth quadruple, sequential, and dual-concomitant (hybrid) regimens are now replacing standard triple therapies as empirical first-line treatments on the basis of the understanding of the local prevalence of H. pylori antimicrobial resistance. Selection of PPI metabolized by the non-enzymatic pathway or minimal first pass metabolism and/or increasing dose of PPI are important to increase H. pylori eradication rates. Therefore, local antibiotic resistance surveillance updates, selection of appropriate first-line regimens with non-enzymatic PPI and/or increased doses of PPI, and detailed evaluation of patients' prior antibiotic usage are all essential information to combat H. pylori antibiotic resistance in Asia.

PMID:
25856059
DOI:
10.3390/molecules20046068
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multidisciplinary Digital Publishing Institute (MDPI)
    Loading ...
    Support Center